| LUDWIG INSTITUTE FOR CANCER RESEARCH Patent applications |
| Patent application number | Title | Published |
|---|
| 20110229469 | METHODS FOR THE TREATMENT OF CANCER - Methods for treating cancer with at least one HGF-Met inhibitor and at least one EGFR inhibitor are provided | 09-22-2011 |
| 20110177079 | Cancer-testis antigens - The invention relates to cancer-testis antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of novel cancer-testis (CT) antigens. | 07-21-2011 |
| 20110150900 | REGULATION OF FATTY ACID TRANSPORTERS - The present invention provides materials and methods for modulating FATP expression and/or activity in vivo. The materials and methods have numerous diagnostic, prophylactic, and therapeutic applications for various diseases and conditions that are influenced by FATPs, or characterized by excessive or inadequate FATP expression or activity. | 06-23-2011 |
| 20110076232 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 03-31-2011 |
| 20090324611 | Targeting VEGF-B Regulation Of Fatty Acid Transporters To Modulate Human Diseases - The present invention provides materials and methods for modulating FATP expression and/or activity in vivo. The materials and methods have numerous diagnostic, prophylactic, and therapeutic applications for various diseases and conditions that are influenced by FATPs, or characterized by excessive or inadequate FATP expression or activity. | 12-31-2009 |
| 20090263394 | A34 AND A33-LIKE 3 DNA PROTEIN, ANTIBODIES THERETO AND METHODS OF TREATMENT USING SAME - Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient. | 10-22-2009 |
| 20090215098 | QUANTIFICATION OF ENZYME ACTIVITY BY MASS SPECTROMETRY - The disclosure relates to methods of quantitatively analyzing the enzymatic activity of enzymes in samples containing a plurality of enzymes, using mass spectrometry. Isotopically labeled standards are employed. Purified enzymes and enzymes from crude cell lysates may be analyzed using the disclosed methods. As little as 0.02 pg of cell lysate may be detected. Also disclosed are kits for providing compositions so as to practice the disclosed methods. | 08-27-2009 |
| 20090214524 | Methods and compositions for regulating cell cycle checkpoints - The invention relates to regulation of cell cycle checkpoints, and the application of such regulation in the treatment of disease, particularly cancer. | 08-27-2009 |
| 20090203124 | MAGE-A3 PEPTIDES PRESENTED BY HLA-DR1 MOLECULES - The invention describes HLA class II binding peptides encoded by the MAGE tumor associated genes, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4 | 08-13-2009 |
| 20090203123 | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per SE, and uses thereof - The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention. | 08-13-2009 |
| 20090117134 | Truncated EGF Receptor - The present invention relates to truncated EGF receptor molecules that exhibit increased binding affinities for EGFR ligands such as EGF and TGF1. The present invention also relates to methods of screening for EGF receptor ligands and methods of treatment which involve the use of these molecules. | 05-07-2009 |
| 20090053817 | FIXED CHARGE REAGENTS - The present invention relates to fixed charge reagents and kits for use in tandem mass spectrometry methods involving multiplex analysis. The compounds of the invention are phenacylamide compounds. The invention also relates to methods for the quantification of for example peptides and proteins by tandem mass spectrometry techniques using said reagents and kits. The reagents and kits of the invention enable multiplexed analysis of several samples in one experiment. | 02-26-2009 |
| 20090047284 | Methods and compositions for PDGF-C activation and inhibition - Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of stimulation. The present invention discloses that tPA is a specific PDGF-C activating protease, and that the CUB-domains in PDGF-CC directly interact with the protease, are required for efficient proteolysis, and released CUB-domains are tPA inhibitors. Preferably, the method and compositions of the present invention are used for simultaneously stimulating, or simultaneously inhibiting, thrombolysis and angiogenesis. | 02-19-2009 |
| 20090041755 | Methods and Compositions For PDGF-D Activation and Inhibition - Methods for inhibiting angiogenesis comprising administering urokinase plasminogen activator (uPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the uPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering uPA or an agonist thereof to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of uPA or an agonist thereof for the methods of stimulation. The present invention discloses that uPA is a specific PDGF-D activatin rotease. | 02-12-2009 |
| 20080299134 | Recombinant Anti-Interleukin-9 Antibodies - The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1. | 12-04-2008 |
| 20080299078 | TUMOR ASSOCIATED AMINO ACIDS AND USES THEREFOR - The invention describes SAGE (sdph3.10) and sdp3.5 tumor associated nucleic acids, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acid molecules, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a sdph3.10 and/or sdp3.5 gene product. | 12-04-2008 |
| 20080286272 | EphA3 Antibodies for the Treatment of Solid Tumors - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors. | 11-20-2008 |
| 20080260756 | Peptide Inhibitors of iASPP - The invention relates to a polypeptide or part thereof which inhibits the apoptotic activity of the tumor suppressor protein p53, and includes screening methods to identify agents which interfere with the activity of the polypeptide. | 10-23-2008 |
| 20080226664 | Colon cancer antigen panel - The invention provides methods, compositions and kits for inducing and/or enhancing an immune response in a subject. The invention in some aspects includes polypeptide and nucleic acid molecules that induce and/or enhance an immune response. In some aspects of the invention, the polypeptide and/or nucleic acid molecules of the invention are useful to induce and/or enhance an immune response in a subject who has or is suspected of having cancer. | 09-18-2008 |
